ABSTRACT
AIM: To evaluate the effect of Intacs SK corneal ring segment implant for treatment of patients with moderate to severe keratoconus, who have clear central cornea and cannot tolerate contact lens. METHODS: In this prospective, non-comparative, interventional case series study performed in Dena Hospital, Shiraz, Iran, thirty-seven eyes of thirty-six patients with moderate to severe keratoconus, clear central cornea, and contact lens intolerance were enrolled and underwent Intacs SK corneal ring segment implantation. Preoperatively, uncorrected distance visual acuity (UCDVA), best-corrected distance visual acuity (BCDVA), central corneal thickness(CCT) and average keratometry (Av-K) were measured and compared with post-operative results at one week, one month, three months, and six months. RESULTS: Mean preoperative UCDVA and BCDVA were (1.32±0.31)logMAR and (1.07±0.27)logMAR, respectively. Av-K was (52.13±0.39)D, and the CCT was (432±39.5)µm. Post-operative examinations showed a clinically significant improvement in both UCDVA and BCDVA (P<0.001). There was also a significant effect based on the time of assessment on both UCDVA and BCDVA and both parameters had a continuous improvement during the follow-up period. Three months after operation there was a statistical significant reduction of Av-K (P=0.0001), but there were no significant changes in CCT (P=0.149). CONCLUSION: Intacs SK corneal ring segment implants seem to be a safe and effective treatment option for patients who have keratoconus, clear central cornea, and contact lens intolerance.
ABSTRACT
BACKGROUND: Cystoid Macular Edema (CME) is one of the most common and sight threatening complications of uveitis. Intravitreal injection of corticosteroids and Anti-VEGF are two routine options for treatment. OBJECTIVE: To compare the effects of intravitreal injections of Bevacizumab and Triamcinolone Acetonide for the treatment of persistent macular edema in non-infectious uveitis. METHODS: In a randomized clinical trial, sixty eyes of 55 patients were enrolled in the study. Patients were divided into two groups with randomized digits table. 29 eyes received 4 mg of intravitreal triamcinolone acetonide, and 31 eyes received 1.25 mg of intravitreal bevacizumab. Two main outcome measures were changes in visual acuity, measured with logarithm of minimal angle of resolution, and central macular thickness, measured with optical coherence tomography. RESULTS: The mean follow-up was 25.3 weeks. The best visual acuities were achieved 6 months after injection in both groups. Improvement in visual acuity at 6 months was achieved in 28/29 (96%) of eyes in Triamcinolone group and in 26/31 (83%) eyes in Bevacizumab group (p=0.196). None of the eyes showed worsening of visual acuity after 6 months. Mean of central macular thickness in the pre-injection time for intravitreal triamcinolone acetonide (IVTA) group was 295.62 µ, and 309.87 µ in intravitreal bevacizumab (IVB) group, which were decreased after six months to 199.27 µ and 221.06 µ, respectively (p<0.001). CONCLUSION: This study shows that IVT and IVB are both effective in improving vision in uveitic CME. Although effects of triamcinolone on Central Macular Thickness (CMT) are more apparent, this superiority is not seen on Best Corrected Visual Acuity (BCVA).
